earnings
confidence high
sentiment neutral
materiality 0.70
BrainStorm Q2 net loss $2.9M; FDA clears Phase 3b NurOwn trial
BRAINSTORM CELL THERAPEUTICS INC.
2025-Q2 EPS reported
-$0.77
- Cash and equivalents total $1.03M as of June 30, 2025.
- Net loss per share improved to $0.34 from $0.60 YoY.
- G&A expenses fell to $1.4M from $2.1M; R&D rose to $1.1M from $0.9M.
- FDA cleared Phase 3b ENDURANCE trial targeting ~200 ALS patients.
- Signed LOI with CDMO Minaris for NurOwn manufacturing for the trial.